NSE · AARTIPHARM · Pharmaceuticals
Aarti Pharmalabs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹580 Cr with net profit ₹62 Cr — a 10.7% net margin, versus 10.31% the period before.
Shareholding
As of 2026-06-30
- Promoter42.86%
- Public41.74%
- FII8.17%
- DII7.22%
1,76,506 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.63× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #31 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,73,629 Cr | 38.11 | 5.67 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,20,143 Cr | 216.48 | 3.49 | 11.27% | 14% |
| Lupin Limited | ₹1,12,127 Cr | 70.41 | 4.99 | 23.76% | 19.4% |
| Zydus Lifesciences Ltd. | ₹1,12,000 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Mankind Pharma Limited | ₹1,08,077 Cr | 194.71 | 6.63 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,478 Cr | 345.42 | 18.19 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,369 Cr | 431.17 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,231 Cr | 100.13 | 2.43 | 9.25% | 10.5% |
| Biocon Ltd. | ₹70,007 Cr | 546.71 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹68,056 Cr | 287.91 | 4.92 | 16.66% | 15.65% |
| Aarti Pharmalabs Limited(this company) | ₹6,192 Cr | 101.34 | 2.91 | 8.22% | 10.25% |
AI analysis
AI-generated · google/gemini-2.5-flashAarti Pharmalabs Limited, operating in the Pharmaceuticals sector, has a market capitalization of Rs 6369 Cr. The company reported a profit margin of 10.25% and revenue growth of 14.17%. Its shares traded between a 52-week high of Rs 969.5 and a low of Rs 585. The promoter holding for the quarter ending June 2026 was 42.8573%.
Positives
- +Revenue growth was 14.17%.
- +Debt-to-equity ratio is low at 0.19.
- +The company has a positive profit margin of 10.25%.
Negatives
- −Promoter holding decreased from 46.4619% in March 2024 to 42.8573% in June 2026.
- −11.08% of promoter shares are pledged as of June 2026, which is an increase from 0% in March 2024.
- −Quarterly net profit declined from Rs 88.34 Cr in March 2025 to Rs 61.12 Cr in March 2026.
Financial performance
For the financial year ending March 2025, Aarti Pharmalabs Limited reported a revenue of Rs 2125.1937 Cr and a net profit of Rs 272.4048 Cr, resulting in an EPS of Rs 30.04. Quarterly revenue for March 2026 was Rs 582.64 Cr, with a net profit of Rs 61.12 Cr.
Profitability & returns
The company’s profitability is indicated by a profit margin of 10.25%. The Return on Equity (ROE) stood at 8.22% and Return on Capital Employed (ROCE) was 9.5885%. The earnings per share (EPS) for the latest available annual data was Rs 19.5.
Balance sheet
Aarti Pharmalabs Limited has a debt-to-equity ratio of 0.19, indicating a relatively low reliance on debt for financing. The book value per share is Rs 234.3.
Ownership & pledges
As of June 30, 2026, promoters held 42.8573% of the company's shares. Public shareholding was 41.7449%, while DIIs held 7.2238% and FIIs held 8.174%. Institutions collectively held 15.3978%. A total of 11.08% of promoter holding was pledged, an increase from 0% in previous quarters.
Regulatory & surveillance
As of the provided data, there is no information indicating that Aarti Pharmalabs Limited is currently under any specific regulatory surveillance measures.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.